The Selexis SUREtechnology Platform™ is a powerful tool in speeding and improving outcomes of protein therapeutic target discovery campaigns.
Most biologics require mammalian posttranslational modifications, such as glycosylation, for optimal activity and hence must be produced in mammalian cells. Therefore, the ideal screening system produces candidate molecules in mammalian cells as early as possible to generate more accurate readouts from the screening assays.
The Selexis SUREvariant screening™ supports target discovery work by allowing the early evaluation of up to 500 candidate molecules expressed with mammalian modifications in the Selexis SURE CHO-M Cell line™. The Selexis SUREvariant screening™ eliminates the need for transient transfections; stable cell lines of the 500 candidates are generated. This minimizes variability in protein expression and post-translation modifications throughout the screening process. Screening early on in the production cell line ensures that the final candidate(s) can be produced at sufficient levels for manufacturing and with the correct post-translational modifications. As a result, Selexis SUREvariant screening™ results in more clinically relevant data earlier and better decision-making with regard to clinical candidates.
Using the Selexis SUREvariant screening™ early in the target discovery process can save approximately 5 to 9 months in development time and can reduce costs by over $500,000 per clinical candidate.
